The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
The benefit of cytoreductive nephrectomy (CN) for overall survival (OS) is unclear in patients with synchronous metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.To determine OS benefit of CN compared with no CN in mRCC patients treated with targeted therapies.Retrospective data from patients with synchronous mRCC (n=1658) from the International Metastatic Renal Cell Carcinoma...
ObjectiveTo determine whether patients with metastatic non‐clear‐cell renal cell carcinoma (RCC) benefit from cytoreductive nephrectomy (CN).
Patients and MethodsWe used the Surveillance, Epidemiology, and End Results (SEER) programme to identify a population‐based sample of 4914 patients diagnosed with metastatic RCC between 2000 and 2009.Of the 4914 patients, 591 had non‐clear‐cell histology.The...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.